Scandion Oncology AS (OSTO:SCOL)
kr 0.075 0.004 (5.63%) Market Cap: 17.61 Mil Enterprise Value: -5.06 Mil PE Ratio: 0 PB Ratio: 0.48 GF Score: 0/100

Q2 2024 Scandion Oncology A/S Earnings Call Transcript

Aug 29, 2024 / 09:00AM GMT
Release Date Price: kr0.16 (+3.23%)
Francois Martelet;S;Chief Executive Officer
Scandian Oncology A

/-

Thank you very much, and welcome again to this Q2 2024 report. Next slide, please. Right, so this is a disclaimer that we will not go through. Next one. Alright. So today, we will go through the CORIST, the CORIST data. Basically, we will go through the performance. This will be done by our CFO, Johnny. And then I will end this call with the near term milestones of Scandion Oncology. Right. Shall we have the next slide, please? Right. So today, the speaker as I said earlier, is myself as a CEO and Johnny, our CFO.

Next slide. Right. So today is an important call. And the reason being that we have fully enrolled our patients into the CORIST trial. Furthermore, we have also achieved MTD. And consequently, we are in a process to finally analyze the full set of data of our CORIST clinical trial. So that's an important milestone that we have achieved at Scandion Oncology over the last few months. And I will come back to that.

With regard to PANTAX. We have released the data actually in H1 of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot